ArticleCureus2025
Lymph Node Ratio: A Novel Prognostic Indicator for Gastric Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Gastric cancer remains one of the most common malignancies and is a leading cause of cancer-related mortality worldwide. Accurate nodal staging is critical for gastric cancer prognosis but is often compromised by "stage migration" and variability in lymph node (LN) harvest inherent in the current AJCC N-staging system. The lymph node ratio (LNR) has emerged as a potentially more reliable prognostic indicator that accounts for the extent of lymphadenectomy. This study aimed to evaluate the prognostic significance of the LNR, determine an optimal cutoff value, and compare its accuracy against the conventional AJCC 8th edition N-stage in patients undergoing curative gastrectomy. Methods and materials This was a single-institution, retrospective cohort study. The study analyzed 85 patients with non-metastatic gastric cancer who underwent surgical treatment between January 2021 and December 2024. Clinicopathological data were collected, and the LNR was calculated and categorized into four groups: LNR1 (0%), LNR2 (1-25%), LNR3 (26-50%), and LNR4 (51-100%). Results The median overall survival (OS) was 26 months. Only 24.7% of patients had an optimal LN dissection (>15 nodes). A higher LNR was strongly associated with poorer survival, with median OS decreasing from 36 months in LNR1 to 17 months in LNR4. Multivariate analysis revealed that LNR was a significant independent prognostic factor for survival (p<0.001), whereas the conventional pN stage was not (p=0.098). Conclusions The LNR is a simple, robust, and independent prognostic indicator for overall survival in patients with gastric cancer, appearing superior to the conventional pN stage. Its use can improve risk stratification, particularly in cases of suboptimal lymphadenectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.